Regulation of Cell Plasticity by Bromodomain and Extraterminal Domain (BET) Proteins: A New Perspective in Glioblastoma Therapy

BET proteins are a family of multifunctional epigenetic readers, mainly involved in transcriptional regulation through chromatin modelling. Transcriptome handling ability of BET proteins suggests a key role in the modulation of cell plasticity, both in fate decision and in lineage commitment during embryonic development and in pathogenic conditions, including cancerogenesis. Glioblastoma is the most aggressive form of glioma, characterized by a very poor prognosis despite the application of a multimodal therapy. Recently, new insights are emerging about the glioblastoma cellular origin, leading to the hypothesis that several putative mechanisms occur during gliomagenesis. Interestingly, epigenome dysregulation associated with loss of cellular identity and functions are emerging as crucial features of glioblastoma pathogenesis. Therefore, the emerging roles of BET protein in glioblastoma onco-biology and the compelling demand for more effective therapeutic strategies suggest that BET family members could be promising targets for translational breakthroughs in glioblastoma treatment. Primarily, Reprogramming Therapy, which is aimed at reverting the malignant phenotype, is now considered a promising strategy for GBM therapy.

Automated summary

BET proteins play a key role in transcriptional regulation and cell plasticity, and they are crucial in the development and pathogenesis of glioblastoma. Epigenome dysregulation associated with loss of cellular identity and functions are emerging as important features of glioblastoma pathogenesis. BET family members could be promising targets for translational breakthroughs in glioblastoma treatment.